Eligible Registrants – AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 19 of 19
The dark side of immunotherapy
Emiliano Calvo
Start Madrid, Madrid, Spain
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 8:00 AM-9:45 AM
Inhibitors of the HSF1 stress pathway derived from phenotypic screening: Targeting non-oncogene addiction in ovarian and other cancers
Paul Workman
The Institute of Cancer Research, London, United Kingdom
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 10:00 AM-11:45 AM
Early lessons from initial acquired resistance to TRK inhibitors
David M Hyman
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
Mechanisms of resistance to tumor-specific vaccination: Beyond PD-1 blockade
Douglas G. McNeel
University of Wisconsin, Madison, WI, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 8:00 AM-9:45 AM
Identification of genes and pathways of immune resistance to IO via analysis of neoadjuvant treatment with anti-PD-1
Drew M Pardoll
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 8:00 AM-9:45 AM
Discovery of BI-3406: a potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors
Marco H Hofmann
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 10:00 AM-11:45 AM
ALK2 open drug discovery: A development path from genes to affordable medicines in DIPG
Aled Edwards
Structural Genomics Consortium, Toronto, ON, Canada
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 10:00 AM-11:45 AM
Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
Geraldine O'Sullivan Coyne
National Cancer Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Phase 1 clinical safety and efficacy of ASN007, a novel oral ERK1/2 inhibitor, in patients with RAS, RAF or MEK mutant advanced solid tumors
Anthony W. Tolcher
NEXT Oncology, San Antonio, TX, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Tri-complex inhibitors of the oncogenic, GTP-bound form of KRASG12C overcome RTK-mediated escape mechanisms and drive tumor regressions in vivo
Christopher J Schulze
Revolution Medicines, Redwood City, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 11:50 AM-12:30 PM
Antibody Drug Conjugates in solid tumors: The model of breast cancer
Giuseppe Curigliano
University of Milan, Milan, Italy
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
Immunotoxins targeting GPC3 for liver cancer
Mitchell Ho
National Cancer Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
Recombinant immunotoxins for hematologic malignancies
Robert Kreitman
National Cancer Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
IL-8 in tumor progression
Claudia Palena
National Cancer Institute, Bethesda, MD, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
BMP signaling in glioblastoma
Kohei Miyazono
University of Tokyo, Tokyo, Japan
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
LIF in cancer
Joan Seoane
Vall d’Hebron Institute of Oncology, Barcelona, Spain
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers
Ahmad Awada
Jules Bordet Institute, Brussels, Belgium
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
Spatially resolved profiling of the tumor-immune microenvironment during neoadjuvant HER2-targeted therapy predicts response
Christina Curtis
Stanford University, Stanford, CA, United States
from 2019 Molecular Targets and Cancer Therapeutics conference on October 29, 2019 4:15 PM-6:00 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 19 of 19